Overview

• The company reported Q2 revenue rose to €260.8 million while net losses fell to €386.6 million driven by its Covid-19 vaccine partnership with Pfizer and heightened R&D investment.
• It reaffirmed a €2.6 billion to €2.8 billion research budget for 2025 to advance over 20 cancer candidates in Phase II/III trials.
• Bristol Myers Squibb will pay a $1.5 billion upfront fee in Q3 for joint development of the BNT327 antibody across more than ten tumor types.
• A pivotal Phase III study in an aggressive breast cancer variant is set to start later this year alongside ongoing late-stage lung cancer trials.
• The pending $1.25 billion CureVac takeover aims to bolster mRNA technology capabilities and resolve a long-running patent dispute.